About Lexeo Therapeutics
Advancing science with curative potential for both cardiovascular and APOE4 associated Alzheimer's disease areas.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- New York, New York
- Founded
- 2018
- Company type
- Privately Held
Based in New York City, Lexeo Therapeutics is a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Building on groundbreaking research from Weill Cornell Medicine and the University of California San Diego, Lexeo partners with preeminent institutions on the cutting edge of gene therapy research. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4 associated Alzheimer's disease programs, and is led by pioneers and experts with decades of collective experience in genetic medicines, rare disease drug development, manufacturing and commercialization.
For more information, please visit www.lexeotx.com.
Company locations
345 Park Avenue South, 6th Floor, New York, New York 10010, US
Locations listed on the company profile. These may include offices outside the United States, and not every location is hiring.
On LinkedIn
- Followers
- 16,861
- People linked to this company
- 92
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.